RTW Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

RTW Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181M	Hold	7,144,524	–	–	1.54%	24
2026 Q1	$159M	Hold	7,144,524	–	–	1.58%	19
2025 Q4	$191M	Hold	7,144,524	–	–	1.91%	14
2025 Q3	$152M	Sell	7,144,524 -1,851,023	-21%	-$43.8M	1.88%	16
2025 Q2	$194M	Buy	8,995,547 +455,430	+5%	+$8.47M	2.76%	13
2025 Q1	$142M	Sell	8,540,117 -165,384	-2%	-$3M	2.17%	17
2024 Q4	$160M	Sell	8,705,501 -5,002,005	-36%	-$80.7M	2.42%	16
2024 Q3	$211M	Hold	13,707,506	–	–	3.05%	12
2024 Q2	$223M	Sell	13,707,506 -121,809	-0.9%	-$1.97M	3.45%	11
2024 Q1	$256M	Buy	13,829,315 +2,575,764	+23%	+$63.8M	3.77%	7
2023 Q4	$352M	Sell	11,253,551 -322,986	-3%	-$7.71M	5.5%	5
2023 Q3	$241M	Buy	11,576,537 +1,793,288	+18%	+$48.7M	5.09%	7
2023 Q2	$234M	Buy	9,783,249 +1,540,385	+19%	+$34.2M	4.46%	8
2023 Q1	$155M	Buy	8,242,864 +4,571,926	+125%	+$87.1M	3.23%	13
2022 Q4	$58.4M	Hold	3,670,938	–	–	1.19%	21
2022 Q3	$60.1M	Sell	3,670,938 -553,171	-13%	-$8.96M	1.38%	25
2022 Q2	$59.5M	Buy	+4,224,109	New	+$78.8M	1.54%	24

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

RTW Investments's ACAD Position: Q2 2026 in Review

RTW Investments held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 7,144,524 shares worth $181M. The position accounts for 1.54% of the portfolio, ranked #24.

RTW Investments first reported a position in ACAD in Q2 2022 and has held it in 17 quarters since. The position peaked at $352M in Q4 2023. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

RTW Investments held 7,144,524 shares of Acadia Pharmaceuticals worth $181M as of Q2 2026.
RTW Investments left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 1.54% of RTW Investments's portfolio in Q2 2026, its #24 holding.
RTW Investments first reported a position in Acadia Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
RTW Investments's Acadia Pharmaceuticals position peaked at $352M in Q4 2023.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.